Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30781780 | 0.91 | TLR2 (0.38) | TLR2TPSAB1PTPN1SIRT5SIRT2 | |
| SCHEMBL27213364 | 0.91 | TLR2 (0.38) | TLR2TPSAB1PTPN1SIRT5SIRT2 | |
| SCHEMBL84123 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL22387795 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL13044093 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL10066102 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL13830419 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL12944386 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL31371875 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL29407919 | 0.90 | CASP3 (0.45) | TLR2PTPN1SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | TLR2 1069/4885TPSAB1 1343/4885PTPN1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.